Peramivir (trade name Rapivab) is an antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. It is approved for intravenous administration.In October 2009, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the use of peramivir based on safety data from phase I, phase II, and limited phase III trial data. The emergency use authorization for peramivir expired in June 2010. On 19 December 2014, the FDA approved peramivir to treat influenza infection in adults. History
An intramuscular (IM) peramivir phase II study for seasonal influenza in 2008–2009 found no effect for the primary endpoint of improvement in the median time to alleviation of symptoms in subjects with confirmed, acute, uncomplicated influenza infection versus placebo. In October 2009, it was reported that the experimental antiviral drug peramivir had been "life-saving" effective in intravenous treating 8 serious cases of swine flu. On October 23, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for peramivir, allowing the use of the drug in intravenous form for hospitalized patients only in cases where the other available methods of treatment are ineffective or unavailable; for instance, if oseltamivir resistance develops and a person is unable to take zanamivir via the inhaled route.
Any form of decreased appetite that leads to changes in the body (such as weight loss or muscle loss) that is not done intentionally as part of dieting is clinically significant. Physiology of anorexia
Appetite stimulation and suppression is a complex process involving many different parts of the brain and body by the use of various hormones and signals. Appetite is thought to be stimulated by interplay between peripheral signals to the brain (taste, smell, sight, gut hormones) as well as the balance of neurotransmitters and neuropeptides  in the hypothalamus. Examples of these signals or hormones include neuropeptide Y, leptin, ghrelin, insulin, serotonin, and orexins (also called hypocretins). Anything that causes an imbalance of these signals or hormones can lead to the symptom of anorexia. While it is known that these signals and hormones help control appetite, the complicated mechanisms regarding a pathological increase or decrease in appetite are still being explored. Common causes
Acute radiation syndrome
Addisons disease
Alcoholism
Alcohol withdrawal
Anemia
Anorexia nervosa
Anxiety
Appendicitis
Babesiosis
Benzodiazepine withdrawal
Bipolar disorder
Cancer
Cannabinoid hyperemesis syndrome
Cannabis withdrawal
Celiac disease
Chronic kidney disease
Chronic pain
Common cold
Constipation
COPD
COVID-19
Crohns disease
Dehydration
Dementia
Depression
Ebola
Fatty liver disease
Fever
Food poisoning
Gastroparesis
Hepatitis
HIV/AIDS
Hypercalcemia
Hyperglycemia
Hypervitaminosis D
Hypothyroidism and sometimes hyperthyroidism
Irritable bowel syndrome
Ketoacidosis
Kidney failure
Low blood pressure
Mania
Metabolic disorders, particularly urea cycle disorders
MELAS syndrome
Nausea
Opioid use disorder
Pancreatitis
Pernicious anemia
Psychosis
Schizophrenia
Side effect of drugs
Stimulant use disorder
Stomach flu
Stress
Sickness behavior
Superior mesenteric artery syndrome
Syndrome of inappropriate antidiuretic hormone secretion
Tuberculosis
Thalassemia
Ulcerative colitis
Uremia
Vitamin B12 deficiency
Zinc deficiency
Infection: Anorexia of infection is part of the acute phase response (APR) to infection. The APR can be triggered by lipopolysaccharides and peptidoglycans from bacterial cell walls, bacterial DNA, and double-stranded viral RNA, and viral glycoproteins, which can trigger production of a variety of proinflammatory cytokines.